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Abstract. A patient treated for 4 months with hydroxy -
carbamide (hydroxyurea) for chronic myelomonocytic
leukemia was admitted to hospital for recently developed
severe dyspnea and acute respiratory failure. The computed
tomographic scan of the chest showed diffuse ground glass
opacities, some centrilobular low-density nodules (resembling
hypersensitivity pneumonitis-like pattern), and minimal
interstitial reticulation of the subpleural region. The analysis
of bronchoalveolar lavage fluid excluded infection, as did
serological examinations. The patient was started on oxygen
therapy and with relief of thrombocytopenia and suspected
hemolytic anemia, hydroxyurea treatment was discontinued.
The patient underwent steroid therapy, with a rapid
progressive improvement of clinical and radiological features.
As hydroxyurea is increasingly used for a number of systemic
disorders, physicians must be aware of its potential lung
toxicity, requiring immediate cessation of the treatment and
empiric corticosteroid therapy.
Hydroxycarbamide (hydroxyurea) is a drug widely indicated
for the treatment of myeloproliferative disorders (chronic
myeloid leukemia) and sickle cell anemia (1-3). As a rule,
this antineoplastic drug is well tolerated (1), and is
commonly used for ovarian neoplasms, squamous cancer of
the head and neck, and glioblastoma multiforme. The most
common toxic effects include hematological alterations
associated with bone marrow failure and T-cell reduction,
thrombocytopenia, anemia and neutropenia (1-3). Other
common side-effects (10% or more) include asthenia,
azoospermia, malaise, dysuria, blood creatinine increase,
disorientation, hallucination, fever, gastrointestinal disorders
(such as pancreatitis, nausea, vomiting, diarrhea, stomatitis,
mucositis, dyspepsia, melena), and dermatological lesions
(vasculitis, alopecia, popular rush, skin atrophy and
exfoliation or ulcers) (1-3). In 1-10% of cases, the drug can
lead to hepatotoxicity, hepatitis and neuropathy. Potential
carcinogenic effects include an increased risk of skin cancer.
Hydroxycarbamide can induce lung toxicity with pulmonary
edema, lung infiltration and dyspnea (4-8), and pulmonary
fibrosis in a minority of patients (5). Herein we report the
clinical history of a patient experiencing acute interstitial
lung injury secondary to hydroxyurea administration. 
Case Report
An 83-year-old man was admitted to our hospital for acute
respiratory distress. The patient was a former smoker with
only 5 pack/years of exposition. The patient’s past clinical
history revealed systemic arterial hypertension, treated with
calcium channel blockers. Twenty years earlier he had
undergone surgery for an abdominal liposarcoma and during
the previous 4 months had started hydroxyurea treatment
(500 mg/day), following the diagnosis of chronic idiopathic
myelofibrosis. The patient complained of breathlessness and
a dry cough, which had worsened over the previous week.
He was afebrile, the arterial blood gas analysis revealed
severe hypoxemia and routine blood tests showed
thrombocytopenia (63,000×106/l). The electrocardiogram
was normal and echocardiography excluded acute heart
failure. The serological microbiological assays revealed an
uncertain positivity for Mycoplasma pneumonia, while blood
cultures were negative. Chest examination revealed bilateral
basal crackles and the chest X-ray showed bilateral diffuse
shadows. The computed tomographic (CT) scan of the chest
excluded pulmonary embolism and showed ground glass
opacities with mosaicism in both lungs. In the upper lobes,
small ground-glass zones were observed. Some centrilobular
low density nodules resembling a hypersensitivity
pneumonitis-like pattern and minimal interstitial reticulation
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of the subpleural regions were observed, especially in the
dorsal parts of lower lobes. Some mediastinal and hilar
lymphadenopathies were also present without pleural or
pericardial effusions (Figure 1). The patient was started on
oxygen therapy and intravenous broad-spectrum antibiotics.
Bonchoscopy with bronchoalveolar lavage was performed.
Microscopy and cultures for mycobacteria, common bacteria,
viruses and fungi were negative. Polymerase chain reaction
for Legionella pneumophila, Chlamydia pneumoniae and
Mycoplasma pneumoniae, Herpes simplex virus (HSV) 1 and
2, Adenovirus and Pneumocystis jiroveci were also negative,
as well as galactomannan and aspergillus antigen tests. The
cytological examination and transbronchial needle aspiration
of the right hilar lymph nodes (station 11 R) excluded
malignant abnormalities. The cellular count in
bronchoalveolar lavage revealed 40% macrophages, 55%
lymphocytes (with a normal CD4/CD8 ratio), and 5%
neutrophils. 
With the relief of thrombocytopenia and suspected
hemolytic anemia, in accordance with hematologists,
hydroxyurea treatment was discontinued. A diagnosis of
interstitial pneumonia associated with acute respiratory failure
was made and we treated the patient with oxygen, low dose
of diuretics, oral azithromycin and low dose of oral steroids
(16 mg/day prednisolone). A month later the patient was
referred to the pulmonologist for examination. Lung function
tests evidenced a mild obstructive syndrome with a moderate-
to-severe reduction of diffusion capacity for carbon monoxide.
The results of arterial blood gas analysis with 2 l/min of O2
were: paO2=69.9 mmHg, paCO2=28.9 mmHg, and pH of 7.45.
After 4 weeks, the abnormal chest radiography and CT findings
had improved, therefore it was decided to increase the amount
of prednisolone to 50 mg/day. Further improvements of the
pulmonary situation were recorded after 3 months and adequate
oxygenation became possible with 1.5 l/min of O2. The
hydroxyurea treatment was not reintroduced and the patient is
stable, his respiratory symptoms are improved as well as the
lung function test parameters and the blood gas analysis. He
requires oxygen only under effort. 
Discussion 
This case report underlines the risk of lung fibrotic toxicity
in patients treated with hydroxyurea for a myeloproliferative
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Figure 1. High-resolution computed tomography of the chest showing diffuse ground-glass opacities (a), bilateral peripheral reticulations (b), areas
of subpleural thickening (c), and bilateral centrilobular low-density nodules (d).
disease. This is a rare event and very few cases have been
reported in the literature (5-12). In this limited population,
the interstitial lung toxicity generally occurred after a few
weeks of exposure to hydroxyurea (9), while in our patient
after 15 weeks. Lung toxicity is usually associated with
dyspnea and fever (5-7). Fever may be the only sign of a
drug reaction, resolving with withdrawal and recurring at re-
challenge (4). As previously found by Cleverley et al. (13)
in a similar case, fever was absent in our patient while
dyspnea was severe, the lung toxicity was mainly
documented by CT scan alterations and discontinuing
hydroxyurea resulted in the improvement of clinical and
radiological conditions. However, hydroxyurea-induced
pneumonia was reported as being lethal in a recent case
report in which steroids were also used at high dose with no
benefit; the disease diagnosis was confirmed after autopsy
and by a drug lymphocyte stimulation test positive for
hydroxyurea (11). 
As suggested by Rossi et al. (8) and others (11-13), the
identification of ground-glass opacities at high resolution CT
scan of the chest in a patient with acute respiratory
symptoms treated with hydroxyurea requires a complex
differential diagnosis with bacterial or viral pneumonitis,
respiratory infections (aggravated by myelosuppressive
therapy), and pulmonary hypertension. In our patient, the
microbiological examinations allowed for exclusion of
infections and the radiological high-resolution CT features
were consistent with the phenomenon of drug-induced lung
toxicity being similar to an hypersensitivity pneumonitis-like
pattern and comparable to a histological picture of diffuse
alveolar damage, already reported in Pneumotox associated
with hydroxyurea exposure (14). 
Mechanisms of hydroxyurea toxicity are unclear and
further research is needed (15-17). This drug is increasingly
used for a number of malignant and non-malignant disorders,
however, as underlined by this case report, it can induce
severe interstitial pneumonitis with diffuse alveolar damage
and radiological pulmonary infiltrates requiring an early
cessation of the treatment and empiric corticosteroid therapy
(17). It is necessary that hematologists and physicians are
aware of the lung toxicity of hydroxyurea and its severe and
potentially life-threatening effects.
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